Literature DB >> 24099282

Predominance of Klebsiella pneumoniae ST14 carrying CTX-M-15 causing neonatal sepsis in Tanzania.

Stephen E Mshana1, Torsten Hain, Eugen Domann, Eligius F Lyamuya, Trinad Chakraborty, Can Imirzalioglu.   

Abstract

BACKGROUND: Klebsiella pneumoniae strains expressing ESBLs are a predominant cause of hospital acquired infections. Here we describe the molecular epidemiology of these isolates in a tertiary hospital in Tanzania, as potential pathogens for neonatal infections.
METHODS: Between April 2009 and March 2010 all Klebsiella pneumoniae isolates with phenotypic expression Extended Spectrum Beta Lactamase (ESBL) were collected and characterized. Identification was done using in house biochemical tests in case of ambiguous results confirmation was done using API 20E. Susceptibility testing was determined using the disc diffusion method followed by specific PCR and sequencing to determine ESBL genes. Phylogenetic analysis, Pulse field gel electrophoresis (PFGE) and Multi-Locus sequence typing (MLST) to PFGE clusters representative isolates were performed to determine clones of the isolates. Conjugation and hybridization were performed to determine the location of blaCTX-M-15 gene.
RESULTS: A total of 92 non-repetitive ESBL producing K. pneumoniae representing 50.3% of Klebsiella pneumoniae isolates were characterized. These isolates were from blood 61 (66%), wound swab 13 (14%), urine 12 (13%) and pus 6 (7%) were analyzed. Most blood culture strains originated from neonatal unit 39/61(64%) and 22 (36%) of the blood culture isolates were from neonatal ICU. All isolates were resistant to gentamicin and 54% were resistant to ciprofloxacin. Using a similarity index of 80%, the isolates were assigned to thirteen clusters based on PFGE patterns and contained sub-clusters with identical strains indicating clonal outbreaks. Cluster X5, X7 and X8, and X9 were grouped into ST48, ST14 and ST348 respectively. Based on gyrA PCR- RFLP phylogenetic analysis all isolates were grouped as KpI. The predominant ESBL allele detected was blaCTX-M-15 which was found in 76% of isolates, followed by blaTEM-104 (19%), blaSHV-11 (3.2%) and blaTEM-176 (2%). The blaCTX-M-15 gene was located in multiple conjugative IncF plasmids ranging from 25 kb-485 kb in size.
CONCLUSION: The high prevalence of blaCTX-M-15 observed among ESBL producing K. pneumoniae in Tanzania, is possibly due to the spread of a common IncFII 145 kb plasmid and of certain clones such as ST14 and ST48. Furthermore the 485 kb plasmid detected is the largest plasmid reported to carry blaCTX-M-15 todate.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24099282      PMCID: PMC3851032          DOI: 10.1186/1471-2334-13-466

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


Background

Gram negative bacteria from clinical settings are increasingly becoming resistant to commonly used antibiotics. Prevalence of extended spectrum β-lactamases in clinical Klebsiella pneumoniae has been reported to be 45-80% in Tanzania [1,2]. While blaCTX-M-15 is the most common ESBL allele among Escherichia coli in Tanzania [3-5], little is known about ESBL alleles in K. pneumoniae. In Tunisia blaCTX-M-15 was the predominant allele among K. pneumoniae isolates and was found in association with IncF plasmids [6]. The excessive use of cephalosporins in clinical practice has resulted in an increase of gram-negative enteric bacteria resistant to these drugs. ESBL genes responsible for resistance are mainly found in mobile genetic elements that can readily spread through bacterial populations [7-9]. ESBL –producing K. pneumoniae usually express resistance to various antibiotics [3,6-9], therefore their antibiotic therapy is limited to a few expensive drugs which, in most cases, are not available in developing countries. The distribution of ESBL alleles varies among countries. The isolation of blaSHV- and blaCTX-M-producing K. pneumoniae has been demonstrated in different multicentre studies [10] and, as in E. coli, the dissemination of ESBLs is due to clonal expansion and/or plasmid transfer [11,12]. Dissemination of major blaCTX-M-15 producing K. pneumoniae epidemic clones ST11, ST15, ST147 and ST258 has been reported in Europe, North America and Asia [11,12]. Very few studies have reported on the problem of ESBL producing K. pneumoniae in Africa especially in sub-Saharan Africa [4,5,13]. In Tanzania blaCTX-M-15 has been demonstrated in one strain of K. pneumoniae[5]. Despite the high prevalence of these isolates in nosocomial infections, large studies to investigate the molecular epidemiology of these isolates in Tanzania are still lacking. We therefore conducted an epidemiological study to determine the molecular epidemiology of ESBL producing K. pneumoniae within the largest tertiary hospital in the Lake Zone of Tanzania.

Methods

Bacterial strains and susceptibility testing

Between April 2009 and March 2010 a total of 1260 clinical specimens were processed of which 700 were from adults, 600 from neonates and 60 from children. One hundred and three non repetitive ESBL producing Klebsiella pneumoniae were obtained from these routine clinical specimens; [blood (61), wound swab (13), urine (12) and pus (6)] were analyzed. All inpatient’s specimens were obtained after a hospitalization time of more than 72hrs. The specimens were processed using standard operative procedures; K. pneumoniae isolates were identified using in-house biochemical profiles which included: Triple-Sugar-Iron, Urease, Voges-Prosgauer, Methyl-Red, citrate utilization, indole production and motility. In case of ambiguous results a further identification using API 20E (BioMerieux, France) was done following the instructions of the vendor. Antibiotic susceptibility was determined using disk diffusion method on Mueller-Hinton agar (Oxoid, Thermo Scientific, UK) as recommended by the Clinical and Laboratory Standard Institute (CLSI) [14]. Susceptibility was tested to 11 antibiotics: ampicillin (10 μg), amoxicillin/clavunate (20/10 μg), tetracycline (30 μg), gentamicin (10 μg), sulfamethoxazole-trimethoprim (1.25/23.75 μg), ciprofloxacin (5 μg), ceftazidime (30 μg), cefepime (30 μg) and meropenem (10 μg) (OXOID, Thermo Scientific, UK). Quality control was performed using Escherichia coli ATCC 25922 reference strain. ESBL screening was performed using MacConkey agar with 30 μg/ml cefotaxime and then confirmed using double disk synergy (Disk approximation method) [9]. Escherichia coli ATCC 25922 was utilized as negative control whereas Klebsiella pneumoniae ATCC 700603 was used as ESBL positive control.

Characterization of ESBLs genes

The presence of ESBL genes was determined by PCR and sequencing using primers targeting blaTEM, blaSHV and blaCTX-M as described previously [9]. Briefly, strains were grown on Luria- Bertani (LB) agar plates with 30 μg/ml cefotaxime and a single colony was used as template in 50 μl PCR mixture as previously described [9]. In all transconjugants the presence of tnpA/ISEcp1 (1.881 kb) was tested by PCR using primers (tnpA F: 5’-GCAGGTGATCACAACC-3’ and tnpA R: 5’-GCGCATACAGCGGCACACTTCCTAAC-3’) as previosuly described [9]. All PCR products were sequenced (LGC genomics GmbH, Berlin, Germany) using the same primers plus an additional set of primers (CTF-F: 5’-GACAGACTATTCATGTTGTTG-3’ and CTF-R:5’-CGATTGCGGAAAAGCACGTC-3’) designed in this study to cover mutations that differentiate blaCTX-M-15 from blaCTX-M-28[15]; the resulting sequence was compared with known sequences using DNASTAR software (DNASTAR Inc, Madison, USA) and the NCBI BLAST algorithm.

Pulsed-field Gel Electrophoresis (PFGE), phylogenetic group typing and MLST

Clonal relatedness between the different strains was studied using PFGE which was performed according to the Pulse Net protocol of the Centre for Disease Control and Prevention (Atlanta, USA). The agarose-embedded DNA was digested with the restriction endonuclease XbaI (Fermentas, Germany) at 37°C for 18hrs. Electrophoresis was conducted using CHEF Drive II (Bio-Rad, UK); conditions were 6V, with 5s-50s pulses for 26hrs. Band patterns were compared using Gelcompar II (Applied Maths, Belgium). Patterns were normalized using a molecular weight marker (Lambda Ladder PFGE Marker, New England Biolabs, USA) [3,9]. Phylogenetic grouping was performed using a rapid method combining gyrA PCR- restricted fragment length polymorphisms analysis (RFLP), parC-PCR and adonitol fermentation as described previously [16]. MLST was performed as described previously for 15 selected isolates based on PFGE clusters [17] (http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html). Briefly, PCR for seven housekeeping genes; rpoB, gapA, mdh, pgi, phoE, infB and tonB was conducted and products directly sequenced. Analysis was carried out as described on the website.

Location of ESBL genes

Conjugation was performed to investigate the transferability of the resistance determinants using plate mating experiments as described previously [9]. Eighteen K. pneumoniae from different PFGE clusters were used as donor and E. coli K12 CC118 (RifR, StrR, Lac-, plasmid-free) as a recipient strain. Transconjugants were selected on Luria Bertani/ lysogeny broth (LB) agar plates supplemented with 30 μg /mL cefotaxime and 300 μg /mL rifampicin and were confirmed for the presence of ESBL genes phenotypically, using the double disk synergy test (DDST) disk approximation method and genotypically, by testing for the presence of the respective ESBL gene via PCR. The frequency of conjugation was expressed relative to the number of donor cells. Plasmid sizing was performed on clinical isolates and transconjugants using S-1 nuclease PFGE as described previously [9]. Southern blotting was performed using overnight capillary transfer (CUMC Protocol for Southern Blot, New York) and hybridization was accomplished using a blaCTX-M-15 DIG labelled probe (DIG High Prime DNA Labelling and Detection Starter Kit II, Roche, Germany) following the manufacturer’s instructions. PCR based replicon typing with confirmatory sequencing was carried out with selected isolates and their transconjugants using primers pairs which recognize FIA, FIB, FII, FrepB, I1, P, A/C, X, HI1,HI2, L/M, FIC, Y, W,T, K and N replicons [7].

Ethical approval

The study was approved by the Bugando Medical Center/Catholic University of Health and Allied Sciences ethics committee and drug susceptibility results were used for routine patient care.

Results

Bacterial strains and susceptibility pattern

A total of 92 K. pneumoniae isolates were confirmed to be ESBL producers, they represented 50.3% of all K. pneumoniae isolated over a period of 12 months. Most of K. pneumoniae producing isolates were from inpatients 87 (94%). The majority of isolates were recovered from blood culture samples from neonatal unit and neonatal ICU (NICU) 59 (64%) (Figure 1). Nineteen isolates (21%) were from wound swabs and pus and twelve (13%) were isolated from urine specimens from various wards (Figure 1). A higher rate of resistance to commonly used non-beta lactams was observed. All isolates were resistant to gentamicin and sulphamethaxazole/trimethoprim; the rate of resistance to tetracycline and ciprofloxacin was 98% and 54% respectively. A total of 25 (38%) isolates from neonatal unit and NICU were resistant to ciprofloxacin compared to 17 (68%) of isolates from other wards (chi-square 5.29, (p = 0.02)). All isolates were sensitive to meropenem using the disc diffusion test (Table 1).
Figure 1

PFGE dendrogram of ESBL–producing . The PFGE patterns of the 92 K. pneumoniae ESBL producers are displayed on the dendrogram. The diagram also shows the isolate numbers, wards, specimens, ESBL alleles, phylogenetic groups as well as the PFGE cluster. Dashed X line indicates SAB of 0.8 revealing 13 clusters (X1-X13). NU, neonatal unit; NICU, neonatal intensive care unit.

Table 1

Susceptibility profile of 92 ESBL producing isolates

Antibiotic%resistanceMean zone diameter ± SD: resistanceMean diameter ± SD: sensitive
Ampicillin (30 μg)
100%
6.06 ± 0.2356 mm
NA
Amoxicillin/Clavulanate(20/10 μg)
100%
10.7 ± 0.428 mm
NA
Tetracycline (30 μg)
98%
6 ± 0.000 mm
17 mm
Gentamicin (10 μg)
100%
6.22 ± 0.428 mm
NA
SXT(1.25/23.75 μg)
100%
6.56 ± 0.856 mm
NA
Ciprofloxacin (5 μg)
54%
8.67 ± 0.485 mm
23.44 ± 0.511 mm
Ceftazidime (30 μg)
100%
13.78 ± 0.428 mm
NA
Cefepime (30 μg)
95.7%
11.3 ± 2.6 mm
22.0 ± 2.8 mm
Meropenem (10 μg)0.00%NA24.4 ± 0.3 mm

NA = not applicable.

PFGE dendrogram of ESBL–producing . The PFGE patterns of the 92 K. pneumoniae ESBL producers are displayed on the dendrogram. The diagram also shows the isolate numbers, wards, specimens, ESBL alleles, phylogenetic groups as well as the PFGE cluster. Dashed X line indicates SAB of 0.8 revealing 13 clusters (X1-X13). NU, neonatal unit; NICU, neonatal intensive care unit. Susceptibility profile of 92 ESBL producing isolates NA = not applicable.

ESBL alleles

Of 103 phenotypically confirmed ESBL producing Klebsiella pneumoniae isolated during study period 92 (89%) were PCR-positive using the primers (CTX-M, TEM, SHV) described in the materials and methods section. Following PCR and sequencing blaCTX-M-15 was the commonest ESBL allele detected. It was found in 70 (76%) of cases. In a majority of isolates 49 (70%), the blaCTX-M-15 allele occurred in combination with blaTEM-1. Also blaCTX-M-15 occurred in combination with blaSHV-11 in 11 (16%) isolates. Other ESBL alleles detected were blaTEM-104 (18%) and blaTEM-176 (2%). BlaCTX-M-15 was the most frequent allele (87%) among isolates from neonatal unit and NICU (Figure 1). In all 18 strains tested the ISEcp1/tnpA element was found upstream of blaCTX-M-15.

Genetic relatedness

The PFGE-based patterns of the isolates were assigned to 13 clusters using a similarity index (SAB) of 0.8 Figure 1. These clusters contained sub-clusters, as shown in Figure 1.Cluster X5 which was assigned to ST48 was found to be clonal. The cluster X7 contained 2 large sub-clusters each with identical strains; one sub-cluster was assigned to ST48 and the other to ST14. All these sub-clusters with identical strains occurred in the neonatal unit and NICU, thus representing outbreaks in these units. The first outbreak occurred in June 2009 isolates in cluster X8, followed by sub-clusters in X7 in January and March 2010. The largest cluster was cluster X7 which contained 28 isolates of which 26 (93%) were from the neonatal unit and NICU. The isolates in this cluster have a single differing fragment thus indicating their close relatedness. The cluster X2, as the second largest, contained diverse isolates from various wards and could further be divided into 4 sub-clusters. Representative strains from this cluster were grouped to ST101 and ST147. Cluster X9 with 6 isolates was assigned to ST348. All K. pneumoniae isolates were grouped in the phylogenetic group KpI using gyrA PCR-RFLP.

Location of bla CTX-M-15 genes and transferability of resistance

Sixteen of 18 Klebsiella pneumoniae isolates, which were randomly selected as donors, were able to transfer resistance at a frequency of 10-3-10-7 transconjugants per donor cell (Table 2). Different sizes of plasmids were found in clinical isolates ranging from 25 kb-485 kb in size and all were found to hybridize to the DIG labelled blaCTX-M-15 probes. A commonly identified 145 kb IncF plasmid was detected in 8 (44%) of the isolates tested. A representative isolate from 11 identical strains in cluster X7 contained 2 plasmids (485 kb and 25 kb). Interestingly this isolate did not transfer resistance by conjugation and both plasmids gave positive signals on hybridization (Figure 2). IncF replicons were found in 12 isolates (66.6%). Gentamicin resistance was transferable in all conjugative cases, Gentamicin-co-trimoxazole (GM-SXT) in 7 (38%), and GM-SXT-TET (Tetracycline) in 3 (16%) cases.
Table 2

Phenotypic and molecular characteristics of 18 representative strains of used as donors

S NOIsolateESBL alleleInc groupPFGE clusterSTPhylConjugation frequencyPlasmid sizeTransferable resistance
1
020
CTX-M-15, TEM-1
FII
X2
ST147
KpI
10-5
145 kb
GM,SXT
2
019
CTX-M-15, TEM-1
FII
X2
ND
KpI
10-7
194 kb
GM
3
025
TEM-104
FII
X2
ST101
KpI
10-7
145 kb
GM,SXT
4
024
TEM-104
ND
X8
ST14
KpI
10-6
194 kb
GM
5
028
CTX-M-15, TEM-1
FII
X8
ST14
KpI
10-6
145 kb
GM
6
175
CTX-M-15
FII
X10
ND
KpI
10-5
97 kb
GM
7
071
CTX-M-15, TEM-1
ND
X2
ST101
KpI
10-6
485 kb
GM
8
008
CTX-M-15, TEM-1
FIA
X7
ST14
KpI
10-5
97 kb
GM
9
107
TEM-104
FII
X8
ST14
KpI
10-5
194 kb
GM
10
108
TEM-104
FIA
X12
ND
KpI
10-3
97 Kb
GM
11
214
CTX-M-15, TEM-1
ND
X7
ST48
KpI
Neg
485 Kb, 25 kb
-
12
120
CTX-M-15, TEM-1
FII
X9
ST348
KpI
10-6
145 kb
GM,SXT
13
133
CTX-M-15
FII
X2
ND
KpI
10-7
145 kb
GM,SXT,TET
14
135
CTX-M-15
FII
X4
ND
KpI
10-3
145 kb
GM,SXT, TET
15
141
CTX-M-15, TEM-1
ND
X9
ST348
KpI
10-5
145 kb
GM,SXT
16
211
CTX-M-15,TEM-1
ND
X5
ST48
KpI
Neg
-
-
17
118
CTX-M-15
ND
X7
ST14
KpI
10-7
97 kb
GM,SXT
18081CTX-M-15FIIX2NDKpI10-6145 kbGM

Inc = Incompatibility; ST = Sequence Type; Phyl = Phylogenetic group; S NO = Strain number; GM = gentamicin; SXT = sulfamethoxazole-trimethoprim; TET = tetracycline.

ND = not determinable.

Figure 2

S1 nuclease PFGE-based sizing of large plasmids for 8 clinical isolates. A) Agarose gel showing S1 nuclease PFGE-based sizing of large plasmids for 8 isolates. M indicates the Lambda molecular weight marker. Plasmid size preparations from isolate number 08, 20, 25, 135, 141, 214 and 175 reveal plasmids with sizes ranging from 25 kb to 485 kb which are indicated with arrowheads; B) shows the corresponding gel after southern blotting and DIG hybridization. Hybridized plasmids are indicated with arrowheads. A small plasmid is labeled with SP; its size of 25 kb was determined after digestion with HindIII, BamHI and EcoRI (data not shown).

Phenotypic and molecular characteristics of 18 representative strains of used as donors Inc = Incompatibility; ST = Sequence Type; Phyl = Phylogenetic group; S NO = Strain number; GM = gentamicin; SXT = sulfamethoxazole-trimethoprim; TET = tetracycline. ND = not determinable. S1 nuclease PFGE-based sizing of large plasmids for 8 clinical isolates. A) Agarose gel showing S1 nuclease PFGE-based sizing of large plasmids for 8 isolates. M indicates the Lambda molecular weight marker. Plasmid size preparations from isolate number 08, 20, 25, 135, 141, 214 and 175 reveal plasmids with sizes ranging from 25 kb to 485 kb which are indicated with arrowheads; B) shows the corresponding gel after southern blotting and DIG hybridization. Hybridized plasmids are indicated with arrowheads. A small plasmid is labeled with SP; its size of 25 kb was determined after digestion with HindIII, BamHI and EcoRI (data not shown).

Discussion

The results of this study provide insights into the molecular epidemiology of ESBL producing K. pneumoniae isolates in a single tertiary hospital in Tanzania, thereby representing the first large-scale study to characterize ESBL producing K. pneumoniae in Tanzania. A high rate of ESBL producing K. pneumoniae isolates is observed as described in various studies [18-21]. The majority of the isolates characterized in this study were from the neonatal- and its intensive care- units. Infections caused by ESBL-producing organisms in neonates are usually reported to be hospital-acquired and associated with invasive procedures [20,22,23]. The predominance of these isolates in these units could be explained by the high use of the third generation cephalosporins, as cefotaxime was the most prescribed drug in the unit during study period. This could further be supported by a significantly (p < 0.05) low rate of resistance towards ciprofloxacin in the neonatal unit and NICU compared to the other wards as ciprofloxacin is usually contraindicated in neonates and children. These units have a high rate of empirical treatment using ampicillin plus gentamicin as first line and cefotaxime as second line antibiotic treatments [20]. As in other studies [22,24] all isolates were found to be resistant to gentamicin and in all cases gentamicin resistance was transferable by conjugation, thus eliminating gentamicin as a treatment option for ESBL producing K. pneumoniae. All isolates were sensitive to meropenem but due to high costs this drug is not commonly used in this hospital. There is a significant difference in the isolation rate of ESBL-producing K. pneumoniae between this study and other studies done previously in Tanzania. This may be due to a variation in the epidemiology of ESBL producing organisms between the hospitals [10]. As in previous studies [25-27] the blaCTX-M-15 allele associated with ISEcp1 was carried on multiple conjugative plasmids of different sizes ranging from 25 kb-485 kb, with one clone having multiple copies of blaCTX-M-15 genes, one copy in the chromosome and two other copies in a 485 kb and a 25 kb plasmid This reflects transmission dynamics of this element, comprising of intra strain mobility on different genetic entities (chromosome, plasmids) within a single isolate, in addition to inter- strain and inter-species transmissibility. Multiple ESBL alleles were observed in which blaCTX-M-15 and blaSHV-11 co-existed in one clone in the neonatal unit; this has recently been described in clinical isolates in Poland as a new strategy of K. pneumoniae to confer resistance to antibiotics [28]. There is an antibiotic selection advantage for the isolates with multiple alleles and multiple copies of genes for an allele as seen in cluster X7 in this study. A high diversity of ESBL producing K. pneumoniae was observed using PFGE and isolates could be divided in 13 clusters at 80% similarity with multiple sub-clusters. In contrast MLST of three large clusters with 46 isolates mainly involved in neonatal sepsis revealed three sequence types 14, 48 and 348; compared to previous reported ST11 and ST15 [19,27,29]. The detection of K. pneumoniae ST14 and ST48 carrying blaCTX-M-15 in a single hospital associated with neonatal nosocomial infection are the first description of the sequence types on the African continent. ST14 and ST48 carrying blaCTX-M-15 could be the predominant clones in Africa, a finding which has to be clarified by further studies from different African countries and underscores the need for joint efforts to survey ESBL-producing isolates in Africa. Recently in Oman a ST14 isolate has been found to harbor blaCTX-M-15 and blaNDM-1, also a ST14 K. pneumoniae carrying blaCTX-M-15 with a similar resistance pattern as described here has been isolated in two patients in Spain from rectal swabs [27]. ST147 and ST101 were detected in cluster X 2 which is the most diverse cluster. These sequence-types have been reported to occur worldwide and are associated with multi-resistant K. pneumoniae[28,29]. Clonal outbreaks caused by ST14 and ST48 were discernible by PFGE. All outbreaks occurred in the neonatal unit and neonatal ICU at different time-points and could be due patient to patient transmission or the acquisition from a common source (contaminated equipments) or from healthcare workers [28-30]. Different clones were involved in all three outbreaks; this further supports the high diversity of these strains in this setting, and represents a huge challenge for the local hospital infection control team. Constant surveillance, sustainable hygiene measures and accurate detection in the hospital are crucial for a quick and appropriate management of these outbreaks [31]. This approach has been used in most developed countries, but can be difficult to implement in a country like Tanzania where availability of even routine culture and susceptibility testing is a major challenge in many hospitals. There is also a need for the hospitals to institute an antibiotic policy guided by antimicrobial stewardship measures such as adaption of empirical treatment regimens to hospital epidemiological susceptibility data. Despite of the fact that these isolates were collected 2009–2010, no major intervention could be instituted until now to control the problem and therefore molecular epidemiology of these isolates is expected to have remained more or less unchanged for the past 3 years.

Conclusion

This study highlights the need to establish an antimicrobial resistance surveillance network in Tanzania for K. pneumoniae and other ESBL-producing Enterobacteriaceae to monitor the trends and new types of resistance mechanisms emerging in hospitals. Also, the factors responsible for the selection and dissemination of this plasmid encoding the blaCTX-M-15 and multiple clones carrying blaCTX-M-15 should be considered for the current clinical management and antibiotic policies, investigated further and controlled to prevent major outbreaks in future.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SEM, EFL, CI, ED and TC designed the study, SEM and CI performed the experiments, SEM, CI, TC analyzed the data, TH analyzed sequences, SEM, CI, ED and TC wrote the manuscript which was corrected and approved by all the other coauthors. All authors read and approved the final manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2334/13/466/prepub
  29 in total

1.  Molecular characterization of a novel plasmid-encoded cefotaximase (CTX-M-12) found in clinical Klebsiella pneumoniae isolates from Kenya.

Authors:  S Kariuki; J E Corkill; G Revathi; R Musoke; C A Hart
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Clonal and horizontal dissemination of Klebsiella pneumoniae expressing SHV-5 extended-spectrum beta-lactamase in a Mexican pediatric hospital.

Authors:  Guadalupe Miranda; Natividad Castro; Blanca Leaños; Adriana Valenzuela; Ulises Garza-Ramos; Teresa Rojas; Fortino Solórzano; Lilia Chihu; Jesús Silva
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

3.  Development of a rapid identification method for Klebsiella pneumoniae phylogenetic groups and analysis of 420 clinical isolates.

Authors:  S Brisse; T van Himbergen; K Kusters; J Verhoef
Journal:  Clin Microbiol Infect       Date:  2004-10       Impact factor: 8.067

4.  Molecular epidemiology of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strains in a university hospital in Tunis, Tunisia, 1999-2005.

Authors:  D Elhani; L Bakir; M Aouni; V Passet; G Arlet; S Brisse; F-X Weill
Journal:  Clin Microbiol Infect       Date:  2009-09-21       Impact factor: 8.067

5.  Characterisation of the CTX-M-15-encoding gene in Klebsiella pneumoniae strains from the Barcelona metropolitan area: plasmid diversity and chromosomal integration.

Authors:  Alicia Coelho; Juan José González-López; Elisenda Miró; Carles Alonso-Tarrés; Beatriz Mirelis; María Nieves Larrosa; Rosa María Bartolomé; Antonia Andreu; Ferran Navarro; James R Johnson; Guillem Prats
Journal:  Int J Antimicrob Agents       Date:  2010-04-13       Impact factor: 5.283

6.  Identification of plasmids by PCR-based replicon typing.

Authors:  Alessandra Carattoli; Alessia Bertini; Laura Villa; Vincenzo Falbo; Katie L Hopkins; E John Threlfall
Journal:  J Microbiol Methods       Date:  2005-06-02       Impact factor: 2.363

7.  Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.

Authors:  B Bedenic; I Goic-Barisic; A Budimir; M Tonkic; L J Mihajkevic; A Novak; M Sviben; V Plecko; V Punda-Polic; S Kalenic
Journal:  J Chemother       Date:  2010-06       Impact factor: 1.714

8.  Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002).

Authors:  Yoichi Hirakata; Junichi Matsuda; Yoshitsugu Miyazaki; Shimeru Kamihira; Sayoko Kawakami; Yukihisa Miyazawa; Yasuo Ono; Nobuhiko Nakazaki; Yasuyoshi Hirata; Matsuhisa Inoue; John D Turnidge; Jan M Bell; Ronald N Jones; Shigeru Kohno
Journal:  Diagn Microbiol Infect Dis       Date:  2005-08       Impact factor: 2.803

Review 9.  Extended-spectrum beta-lactamases: a clinical update.

Authors:  David L Paterson; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2005-10       Impact factor: 26.132

10.  Risk factors for colonisation of newborn infants during an outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in an intermediate-risk neonatal unit.

Authors:  V C Cassettari; I R da Silveira; M Dropa; N Lincopan; E M Mamizuka; M H Matté; G R Matté; P R Menezes
Journal:  J Hosp Infect       Date:  2009-01-14       Impact factor: 3.926

View more
  38 in total

1.  Diversity of clonal types of Klebsiella pneumoniae causing infections in intensive care neonatal patients in a large urban setting.

Authors:  Livia Helena Justo-da-Silva; Andrea Nunes De-Azeredo; Arnaldo Costa Bueno; Lara Feital Montezzi; Maria Beatriz Gerardin Poirot Leobons; Maria Silvana Alves; Patrícia de Souza Inhaquite; Rosana Rangel Santos; Valéria Brígido Carvalho Girão; Antônio José Ledo Alves da Cunha; Carmem Lucia Pessoa-Silva; Renata Cristina Picão; Cristina Barroso Hofer; Guilherme Santoro-Lopes; Lee Woodland Riley; Beatriz Meurer Moreira
Journal:  Braz J Microbiol       Date:  2019-08-10       Impact factor: 2.476

2.  Spread of Plasmid-Encoded NDM-1 and GES-5 Carbapenemases among Extensively Drug-Resistant and Pandrug-Resistant Clinical Enterobacteriaceae in Durban, South Africa.

Authors:  Torunn Pedersen; John Osei Sekyere; Usha Govinden; Krishnee Moodley; Audun Sivertsen; Ørjan Samuelsen; Sabiha Yusuf Essack; Arnfinn Sundsfjord
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

3.  Molecular epidemiology of virulence and antimicrobial resistance determinants in Klebsiella pneumoniae from hospitalised patients in Kilimanjaro, Tanzania.

Authors:  Tolbert Sonda; Happiness Kumburu; Marco van Zwetselaar; Michael Alifrangis; Blandina T Mmbaga; Ole Lund; Gibson S Kibiki; Frank M Aarestrup
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-07-20       Impact factor: 3.267

4.  Characterization of multidrug-resistant and virulent Klebsiella pneumoniae strains belonging to the high-risk clonal group 258 (CG258) isolated from inpatients in northeastern Brazil.

Authors:  Rafael Nakamura-Silva; Mariana Oliveira-Silva; João Pedro Rueda Furlan; Eliana Guedes Stehling; Carlos Eduardo Saraiva Miranda; André Pitondo-Silva
Journal:  Arch Microbiol       Date:  2021-06-10       Impact factor: 2.552

5.  Molecular epidemiology and characterization of an outbreak causing Klebsiella pneumoniae clone carrying chromosomally located bla(CTX-M-15) at a German University-Hospital.

Authors:  Stephen E Mshana; Moritz Fritzenwanker; Linda Falgenhauer; Eugen Domann; Torsten Hain; Trinad Chakraborty; Can Imirzalioglu
Journal:  BMC Microbiol       Date:  2015-06-17       Impact factor: 3.605

Review 6.  Genetic Determinants of Resistance among ESBL-Producing Enterobacteriaceae in Community and Hospital Settings in East, Central, and Southern Africa: A Systematic Review and Meta-Analysis of Prevalence.

Authors:  Onduru G Onduru; Rajhab S Mkakosya; Said Aboud; Susan F Rumisha
Journal:  Can J Infect Dis Med Microbiol       Date:  2021-06-02       Impact factor: 2.471

7.  Prevalence and Antimicrobial Resistance of Microbes Causing Bloodstream Infections in Unguja, Zanzibar.

Authors:  Annette Onken; Abdulrahman K Said; Melissa Jørstad; Pål A Jenum; Bjørn Blomberg
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

8.  Predominance of multi-resistant gram-negative bacteria colonizing chronic lower limb ulcers (CLLUs) at Bugando Medical Center.

Authors:  Nyambura Moremi; Martha F Mushi; Mbunda Fidelis; Phillipo Chalya; Mariam Mirambo; Stephen E Mshana
Journal:  BMC Res Notes       Date:  2014-04-04

9.  Carbapenemase genes among multidrug resistant gram negative clinical isolates from a tertiary hospital in Mwanza, Tanzania.

Authors:  Martha F Mushi; Stephen E Mshana; Can Imirzalioglu; Freddie Bwanga
Journal:  Biomed Res Int       Date:  2014-02-24       Impact factor: 3.411

10.  CTX-M-15 Positive Escherichia coli and Klebsiella pneumoniae Outbreak in the Neonatal Intensive Care Unit of a Maternity Hospital in Ha'il, Saudi Arabia.

Authors:  Mohammed Almogbel; Ahmed Altheban; Mohammed Alenezi; Khalid Al-Motair; Godfred A Menezes; Mohammed Elabbasy; Sahar Hammam; John P Hays; Mushtaq A Khan
Journal:  Infect Drug Resist       Date:  2021-07-23       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.